We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Smith & Nephew Plc | SN. | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.60 | -0.06% | 982.80 | 12:24:16 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 982.60 | 974.00 | 987.40 | 983.40 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 16/4/2024 13:00 by justiceforthemany Anyone bothered to contact Investor Relations? |
Posted at 28/3/2024 16:47 by justiceforthemany Rather than expressing your unhappiness here stakeholders need to be proactive and speak to Investor RelationsKatherine (Head) 07811 270734 Deepak and his frequent share sales needs the boot for one. Has Soames not bought any stock either? |
Posted at 13/10/2023 10:33 by pugugly trading update for the period ended 30 September 2023 on Thursday, 2 November 2023 at 7.00am GMT / 3.00am EDT. This will be followed by a conference call for financial analysts at 8.30am GMT / 4.30am EDT, details of which will be published on the Smith+Nephew website at Enquiries |
Posted at 12/10/2023 09:35 by laurence llewelyn binliner #Essential Investor - thanks, historic margin loss is why the company is on a 10 year low, I am looking for reasons why it may have bottomed out and offer growth going forward up from the 15.3% margin from H1, in an attempt to establish if this is a reasonable entry point...2023 FY outlook - increased full year underlying revenue growth guidance of 6.0% to 7.0% (previously 5.0% to 6.0%), unchanged trading profit margin guidance, expected to be at least 17.5%.. Debt interest will be close to peaking out soon and could subside from 2024 impacting all indebted companies.. |
Posted at 11/10/2023 19:13 by laurence llewelyn binliner New potential investor here looking in at opportunity..No more dividends until May 2024 and sitting at a 10 year low SP, is there much to prop this share up and drive a turnaround growth story..? Or is it all down to the debt pile hurting much like everything else in the red..? 03.08.2023 - The net interest charge within reported results was USD44M, with the change due to an increase in net debt year on year and an increase in the overall weighted average interest rate given the prevailing higher rate environment. The groups net debt excluding lease liabilities, increased from USD2.3BN at 31 December 2022 to USD2.65BN at 1 July 2023 with committed facilities of USD3.7BN We expect to finish 2023 with leverage of 2.0x, unchanged year-on-year. 2023 FY outlook - increased full year underlying revenue growth guidance of 6.0% to 7.0% (previously 5.0% to 6.0%) unchanged trading profit margin guidance, expected to be at least 17.5% |
Posted at 25/8/2022 11:56 by 1bearbull It cannot help in terms of investor confidence when in his first major public appearance he announces a profits warning and if I remember correctly the share fell by 10%. |
Posted at 10/8/2021 15:45 by essentialinvestor Look through the director dealing announcements over the last 6 months.A couple of senior employees in leadership roles appear to have sold and now don't seem to hold a single share in the Company?. That being said, now trading at a level I mentioned a few months back as a target price. There is no comparison with Stryker, it's risible to even mention the two in the same breath. Stryker's record is exceptional. Also worth considering some of the broker views, SN. lack a cementless knee product ATM and this is arguable proving costly. But ultimately the shares are no where near cheap even at current levels. Speculative buy at best Imv. |
Posted at 03/8/2021 13:18 by spoole5 Essential investor called this right |
Posted at 09/6/2021 12:16 by 1nf3rn0 Credit Suisse upgraded shares of artificial hip and knee maker Smith & Nephew on Wednesday to 'outperform' from 'neutral', lifting the price target to 1,805p from 1,560p as it pointed to "underappreciated growth drivers".The bank argued that S&N is an underappreciated elective surgery recovery play in the near term and that investors underestimate the combined power of recently-acquired growth drivers with corresponding return leverage mid-term.It upped its FY21-23 sales/adjusted earnings per share estimates by an average 2%/6%, leaving it 3%/5% above Bloomberg consensus."As the drivers become clearer gaining the confidence of investors, we expect Smith & Nephew stock to reverse its material underperformance over the past 12 months," Credit Suisse said.The bank noted that since late 2017, Smith & Nephew has bought several bolt-on technologies, committing close to $1.6bn, and with associated negative M&A effects on trading margin of around 150 basis points for FY21."We deep-dived into the potential for the new technologies," it said. "We believe the Wound Biologics/Sports Medicine/Extremities |
Posted at 10/5/2020 09:36 by philanderer MIDAS SHARE TIPS: Hip replacement company Smith & Nephew can ease the pain of lockdown for investors |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
